1. A horse racing board game comprising:
a game board having a starting gate, a finish line, and eleven oval shaped lanes between said starting gate and said finish line; and
eleven game pieces movable along said lanes from said starting gate to said finish line, each of said game pieces in the form of a horse and rider; and
each of said lanes having a lane number from a two through a 12 and also having an amount of positions represented as horseshoes between said starting gate and said finish line; and
a holding stable represented by a table space having a column printed with a specific game currency indicia of 1 dollar, 2 dollars, 3 dollars, and 4 dollars, and a row printed with an order of removal indicia of 1st, 2nd, 3rd, and 4th, within which four of said game pieces corresponding to four of said lanes are placed and removed from said lanes; and
said holding stable centrally placed on said game board; and
a game currency having the values of one, two, three, five, and 10; and
a deck of enumerated players cards numbered said two through 12 corresponding to said lane numbers; and
four non-duplicates of said enumerated players cards randomly selected from said deck representing four of said game pieces from said numbers of said lanes within said holding stable; and
said amount of positions prior to said finish line for each of said lanes defined by an equation of n multiplied by 36 multiplied by a probability of a pair of dice rolling the lane number on a single roll where n is an integer value greater than zero; and
said amount of positions prior to said finish line represented by two for said lane two, four for said lane three, six for said lane four, eight for said lane five, ten for said lane six, 12 for said lane seven, ten for said lane eight, eight for said lane nine, six for said lane 10, four for said lane 11, two for said lane 12.
2. The horse racing board game as set forth in claim 1, further comprising:
said holding stable located on said game board; and
said table space within said holding stable having 16 spaces assigning said game currency value to the game pieces placed within said holding stable.
3. The horse racing board game as set forth in claim 2, further comprising:
said deck of enumerated players cards having four of each of said enumerated cards per said deck.
4. The horse racing board game as set forth in claim 3, whereby:
said pair of dice rolling the lane number allow a one position move of said game piece within said lane number toward said finish line; and
said game piece within said lane number which reaches said finish line representing a distribution of a game pot pursuant to said enumerated players cards within a possession of one or more players; and
said enumerated players cards having said lane numbers represented by said game pieces within said holding stable discarded without a payment by said players into said game pot.
5. The horse racing board game as set forth in claim 4, whereby:
said pair of dice rolling the lane number for said lane number represented within said holding stable requiring an amount of said game currency placement within said game pot corresponding to said intersection of a specific game currency value.
6. The horse racing board game as set forth in claim 5, whereby:
said lanes have a substantially oval form and said holding stable is located within said substantially oval form.
said game pieces within said lane numbers remaining at said starting gate upon one or more of said game pieces within said lane numbers reaching said finish line requiring placement of a penalty amount of currency into said game pot by one or more of said players having said possession of said enumerated players cards corresponding to said lanes remaining at said starting gate.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula (I),
or a pharmaceutically suitable salt or prodrug thereof, wherein
– – – is absent or is a bond;
m, n are each independently 0, 1 or 2;
p is 1 or 2;
q and r are each independently 0 or 1;
s is 0, 1, 2, 3, or 4;
R1 is selected from the group consisting of alkyl, alkoxyalkyl, alkylcarbonyl, cyano, cyanoalkyl, halo, haloalkyl, R4O2C\u2014, RcRdNC(O)\u2014, and RcRdNS(O)2\u2014;
R2 is selected from the group consisting of aryl, cycloalkyl, heteroaryl, heterocycle, \u2014O(Rh), and ReRfN\u2014;
R3 is selected from the group consisting of alkyl, alkoxyalkyl, haloalkyl, hydroxyalkyl, R5-C(O)\u2014, R5-C(\u2550N\u2014ORp)-, R6OC(O)\u2014, RgRjNC(O)\u2014, R5-S(O)2-, and RgRjNS(O)2-;
R4 is selected from the group consisting of alkyl, arylalkyl, haloalkyl, heteroarylalkyl, and heterocyclealkyl;
R5, at each occurrence, is selected from the group consisting of alkyl, alkoxyalkyl, aryl, cycloalkyl, haloalkyl, heteroaryl, and heterocycle;
R6 is selected from the group consisting of alkyl, arylalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclealkyl, and heteroarylalkyl;
Rc and Rd, at each occurrence, are each independently selected from the group consisting of hydrogen and alkyl, or Rc and Rd together with the nitrogen atom to which they are attached form a heterocyclic ring;
Re is selected from the group consisting of hydrogen, alkyl, cycloalkyl, and alkylcarbonyl;
Rf is selected from the group consisting of hydrogen and alkyl;
Rg, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, heteroarylalkyl, heterocyclealkyl, and heterocyclealkyl;
Rj, at each occurrence, is independently selected from the group consisting of hydrogen, alkyl, and haloalkyl;
Rh is a cycloalkyl ring optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, haloalkyl, arylalkyl, heteroarylalkyl, cycloalkyl, and heterocyclealkyl; and
Rp is selected from the group consisting of hydrogen and alkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein
m is 0;
n is 1;
p is 1;
q is 0;
r is 0; and
– – – is absent.
3. The compound according to claim 2, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is R5-C(O)\u2014.
4. The compound according to claim 3, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
5. The compound according to claim 3, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
6. The compound according to claim 2, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is R6OC(O)\u2014.
7. The compound according to claim 6, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
8. The compound according to claim 6, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
9. The compound according to claim 2, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is RgRjNC(O)\u2014.
10. The compound according to claim 9, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
11. The compound according to claim 9, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
12. The compound according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, wherein
m is 1;
n is 0;
p is 1;
q is 0;
r is 0; and
– – – is absent.
13. The compound according to claim 12, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is R5-C(O)\u2014.
14. The compound according to claim 13, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
15. The compound according to claim 13, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
16. The compound according to claim 12, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is R6OC(O)\u2014.
17. The compound according to claim 16, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
18. The compound according to claim 16, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
19. The compound according to claim 12, or a pharmaceutically acceptable salt or prodrug thereof, wherein R3 is RgRjNC(O)\u2014.
20. The compound according to claim 19, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of aryl, cycloalkyl, and heteroaryl.
21. The compound according to claim 19, or a pharmaceutically acceptable salt or prodrug thereof, wherein R2 is selected from the group consisting of \u2014O(Rh) and ReRfN\u2014.
22. The compound according to claim 1 or a pharmaceutically acceptable salt or prodrug thereof, selected from the group consisting of
ethyl 2-{(2,2,3,3-tetramethylcyclopropyl)carbonylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
ethyl 2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
ethyl 2-(hexahydro-2,5-methanopentalen-3a(1H)-ylcarbonyl)amino-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
N-{3-(3,3-difluoroazetidin-1-yl)carbonyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl}-2-fluoro-6-(trifluoromethyl)benzamide;
N-3-(azetidin-1-ylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-2-fluoro-6-(trifluoromethyl)benzamide;
2-fluoro-N-{3-(3-methoxyazetidin-1-yl)carbonyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl}-6-(trifluoromethyl)benzamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-propyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
N3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-2-fluoro-6-(trifluoromethyl)benzamide;
N-cyclobutyl-2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
N-cyclopentyl-2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-(2-methoxyethyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-(2R)-tetrahydrofuran-2-ylmethyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-(2S)-tetrahydrofuran-2-ylmethyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
2-fluoro-N-3-(2-furoyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-6-(trifluoromethyl)benzamide;
N-3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-N\u2032-(1,1-dimethylpropyl)urea;
N-3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-N\u2032-cyclopentylurea;
N-3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-N\u2032-(1,2,2-trimethylpropyl)urea;
ethyl 2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxylate;
N-3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthien-2-yl-N\u2032-(1,2-dimethylpropyl)urea;
ethyl 2-(hexahydro-2,5-methanopentalen-3a(1H)-ylcarbonyl)amino-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxylate;
N-{3-(3,3-difluoroazetidin-1-yl)carbonyl-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthien-2-yl}-2-fluoro-6-(trifluoromethyl)benzamide;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-propyl-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxamide;
N-{3-(3,3-difluoroazetidin-1-yl)carbonyl-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthien-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide;
ethyl 2-({(1R,2S,5R)-2-isopropyl-5-methylcyclohexyloxy}carbonyl)amino-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
ethyl 2-{5-chloro-2-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
ethyl 2-{3-chloro-2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
2-(hexahydro-2,5-methanopentalen-3a(1H)-ylcarbonyl)amino-N-propyl-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxamide;
2-(hexahydro-2,5-methanopentalen-3a(1H)-ylcarbonyl)amino-N-(3,3,3-trifluoropropyl)-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxamide;
ethyl 2-(isoquinolin-1-ylcarbonyl)amino-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N-(3,3,3-trifluoropropyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
N-ethyl-2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
N-cyclopentyl-2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthiophene-3-carboxamide;
propyl 2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
2-{2-fluoro-6-(trifluoromethyl)benzoylamino}-N,N-dimethyl-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxamide;
N-{3-(3-methoxyazetidin-1-yl)carbonyl-5,6,7,8-tetrahydro-4H-4,7-epoxycycloheptabthien-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide;
ethyl 2-({(1R,2S,5R)-5-methyl-2-(1-methyl-1-phenylethyl)cyclohexyloxy}-carbonyl)amino-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate;
propyl 2-{2-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate; and
ethyl 2-{2-(trifluoromethyl)benzoylamino}-5,6,7,8-tetrahydro-4H-5,8-epoxycycloheptabthiophene-3-carboxylate.
23. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.
24. A method for treating pain in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.
25. A method for treating nociceptive pain in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.
26. A method for treating neuropathic pain in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.
27. A method for providing neuroprotection in a mammal in need thereof comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof.